WO2002080952A3 - Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways - Google Patents

Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways Download PDF

Info

Publication number
WO2002080952A3
WO2002080952A3 PCT/GB2002/001666 GB0201666W WO02080952A3 WO 2002080952 A3 WO2002080952 A3 WO 2002080952A3 GB 0201666 W GB0201666 W GB 0201666W WO 02080952 A3 WO02080952 A3 WO 02080952A3
Authority
WO
WIPO (PCT)
Prior art keywords
signalling pathway
modulators
identification
hedgehog signalling
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001666
Other languages
French (fr)
Other versions
WO2002080952A2 (en
Inventor
Jonathan Robert Lamb
Gerard Francis Hoyne
Margaret Jane Dallman
Brian Robert Champion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Ltd
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0108873A external-priority patent/GB0108873D0/en
Priority claimed from GB0108872A external-priority patent/GB0108872D0/en
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Priority to AU2002247847A priority Critical patent/AU2002247847A1/en
Priority to JP2002578991A priority patent/JP2004534743A/en
Priority to EP02716928A priority patent/EP1401469A2/en
Publication of WO2002080952A2 publication Critical patent/WO2002080952A2/en
Priority to US10/682,230 priority patent/US20040126359A1/en
Anticipated expiration legal-status Critical
Publication of WO2002080952A3 publication Critical patent/WO2002080952A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)

Abstract

Use of a modulator of a Hedgehog signalling pathway, or a modulator of a pathway which is a target of the Hedgehog signalling pathway in the preparation of a medicament for treatment of a disease or disorder associated with a T-cell mediated disease or disorder.
PCT/GB2002/001666 2001-04-09 2002-04-09 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways Ceased WO2002080952A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002247847A AU2002247847A1 (en) 2001-04-09 2002-04-09 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
JP2002578991A JP2004534743A (en) 2001-04-09 2002-04-09 Hedgehog
EP02716928A EP1401469A2 (en) 2001-04-09 2002-04-09 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
US10/682,230 US20040126359A1 (en) 2001-04-09 2003-10-09 Hedgehog

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0108873A GB0108873D0 (en) 2001-04-09 2001-04-09 Hedgehog
GB0108872A GB0108872D0 (en) 2001-04-09 2001-04-09 Hedgehog and notch
GB0108872.3 2001-04-09
GB0108873.1 2001-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/682,230 Continuation-In-Part US20040126359A1 (en) 2001-04-09 2003-10-09 Hedgehog

Publications (2)

Publication Number Publication Date
WO2002080952A2 WO2002080952A2 (en) 2002-10-17
WO2002080952A3 true WO2002080952A3 (en) 2004-01-08

Family

ID=26245948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001666 Ceased WO2002080952A2 (en) 2001-04-09 2002-04-09 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways

Country Status (5)

Country Link
US (1) US20040126359A1 (en)
EP (1) EP1401469A2 (en)
JP (1) JP2004534743A (en)
AU (1) AU2002247847A1 (en)
WO (1) WO2002080952A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035020A2 (en) 1997-02-10 1998-08-13 The Presidents And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2386190C (en) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
ES2623711T3 (en) 2000-10-13 2017-07-12 Curis, Inc. Hedgehog antagonists, procedures and related uses
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7897588B2 (en) 2002-08-29 2011-03-01 The Regents Of The University Of California Agents and methods for enhancing bone formation
US6837966B2 (en) * 2002-09-30 2005-01-04 Tokyo Electron Limeted Method and apparatus for an improved baffle plate in a plasma processing system
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US20080057071A1 (en) * 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
WO2005060992A1 (en) 2003-12-24 2005-07-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic agents and uses therefor
DK1730280T3 (en) 2004-03-26 2019-02-04 Curis Inc RNA interference modulators for hedgehog signaling and applications thereof
CN1981054A (en) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 Methods for treating cancer using anti-WNT2 monoclonal antibodies and sirna
CA2567330A1 (en) 2004-05-21 2005-12-01 The Regents Of The University Of California Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
ES2389080T3 (en) 2004-06-11 2012-10-23 Riken Drug presenting a regulatory cell ligand contained in the liposome
EP2316832B1 (en) * 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
US20070059311A1 (en) * 2005-09-12 2007-03-15 Jingwu Xie Regulation of the hedgehog signaling pathway and uses thereof
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
JP2010504965A (en) * 2006-09-27 2010-02-18 アイアールエム・リミテッド・ライアビリティ・カンパニー Methods and compositions for treating lymphoma and myeloma
AU2007339325A1 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
NZ579356A (en) 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
PE20090188A1 (en) * 2007-03-15 2009-03-20 Novartis Ag HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE HEDGEHOG PATH
US20100112030A1 (en) * 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2009073186A1 (en) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009086416A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
JP6141015B2 (en) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． Enzymatic transamination of cyclopamine analogues.
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2856291C (en) * 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US9095579B2 (en) * 2012-02-07 2015-08-04 The Regents Of The University Of California Protection and treatment against influenza infection
GB201204645D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Treatment of disease
KR20150013232A (en) 2012-05-07 2015-02-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
EP2844271B1 (en) 2012-05-17 2018-02-28 Paranta Biosciences Limited Use of follistatin or of an activin inhibitor for preventing or treating tissue graft dysfunction
CN102787117A (en) * 2012-07-20 2012-11-21 苏州大学 Small RNA used for regulating expression of B7-H2 gene
KR102156616B1 (en) * 2012-09-26 2020-09-16 쿠크 바이오텍 인코포레이티드 Medical device design, manufacture and testing systems
WO2014058464A1 (en) * 2012-10-09 2014-04-17 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9504732B2 (en) 2013-01-14 2016-11-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for treating myocardial infarction comprising administering sonic hedgehog
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
CN105263500A (en) 2013-05-02 2016-01-20 加利福尼亚大学董事会 Bone-selective osteogenic oxysterol-bone targeting agents
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015073691A1 (en) * 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (en) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 Inhibitors of cyclin-dependent kinases
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN110856722A (en) * 2018-08-26 2020-03-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) Use of Cyclotaxin or its derivatives
CN109187941B (en) * 2018-08-31 2022-04-29 暨南大学 Application of CD4+ CD70+ T cell subset in preparation of kit for auxiliary diagnosis of very severe aplastic anemia
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
JP7660063B2 (en) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of cyclin-dependent kinase 7 and their uses
CN113528521A (en) * 2021-07-08 2021-10-22 安徽农业大学 siRNA and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010364A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010364A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LENDECKEL U ET AL: "Inhibition of alanyl-aminopeptidase suppresses the activation-dependent induction of glycogen synthase kinase-3beta (GSK-3beta) in human T cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 24 JUN 2000, vol. 273, no. 1, 24 June 2000 (2000-06-24), pages 62 - 65, XP002237295, ISSN: 0006-291X *
SALDANHA G: "The Hedgehog signalling pathway and cancer.", THE JOURNAL OF PATHOLOGY. ENGLAND APR 2001, vol. 193, no. 4, April 2001 (2001-04-01), pages 427 - 432, XP008015850, ISSN: 0022-3417 *
See also references of EP1401469A2 *

Also Published As

Publication number Publication date
EP1401469A2 (en) 2004-03-31
US20040126359A1 (en) 2004-07-01
WO2002080952A2 (en) 2002-10-17
AU2002247847A1 (en) 2002-10-21
JP2004534743A (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2002080952A3 (en) Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
EE200300212A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic diseases
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
WO2004010975A3 (en) Controlled drug delivery
WO2002099060A3 (en) Dgks as modifiers of the p53 pathway and methods of use
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
WO2002099053A3 (en) Slc22as as modifiers of the p53 pathway and methods of use
ZA200107315B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury.
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
AU2003202075A1 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
AU2003226537A1 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
AU2001243515A1 (en) Combination drug therapy
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002049647A3 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2003006611A3 (en) GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
AU2001241045A1 (en) Preventive or therapeutic drugs for eye diseases
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use
HK1049120A (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
HK1057996A (en) Combination therapy for the treatment of estrogen-sensitive disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10682230

Country of ref document: US

Ref document number: 2002578991

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002716928

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002716928

Country of ref document: EP